Tag: Gastrointestinal Therapeutics Market – Global Gastrointestinal Therapeutics Industry Size

  • Gastrointestinal Therapeutics Market Size In 2026: Regional Growth, Key Segments And Future Outlook

    Gastrointestinal Therapeutics Market Size In 2026: Regional Growth, Key Segments And Future Outlook

    Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

    Gastrointestinal Therapeutics Market Size Forecast: How Big Could The Market Get By 2030?

    The gastrointestinal therapeutics market has shown robust growth in recent years. It is anticipated to expand from $42.3 billion in 2025 to $44.72 billion in 2026, registering a compound annual growth rate (CAGR) of 5.7%. The market’s historical expansion stemmed from various factors, including the constrained availability of biologics and advanced gastrointestinal therapies, a rising occurrence of acid reflux and ulcers, a dependency on hospital and clinic-based treatment, growing public awareness concerning digestive health, and the widespread use of traditional over-the-counter antacids and laxatives.

    The gastrointestinal therapeutics market size is projected for substantial expansion over the upcoming years. It will grow to $55.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is propelled by factors such as the development of targeted biologics and immunotherapies, the expansion of ambulatory surgical centers and diagnostic laboratories, increased adoption of oral and intravenous delivery systems, growing online pharmacy penetration, and advancements in probiotics and digestive enzyme formulations. Key trends observed within the forecast period encompass a rising prevalence of gastrointestinal disorders, a greater uptake of biologics and advanced therapies, an increase in over-the-counter therapeutics, an intensified focus on personalized gastrointestinal treatments, and expanding online and retail pharmacy distribution.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=19972173&type=smp&name=Gastrointestinal%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Gastrointestinal Therapeutics Market Development Factors: What’s Supporting Demand?

    The increasing prevalence of inflammatory bowel diseases is projected to stimulate the expansion of the gastrointestinal therapeutics market moving forward. Inflammatory bowel disease (IBD) is a persistent condition characterized by inflammation of the digestive tract, primarily involving Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases can be attributed to genetic susceptibility, which causes an abnormal immune response to gut microbes. Gastrointestinal therapeutics play a crucial role in managing and treating bowel diseases by targeting underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, data from the IBD Registry, a UK-based non-profit organization, indicated that over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Hence, the escalating occurrence of inflammatory bowel diseases is fueling the growth of the gastrointestinal therapeutics market.

    Gastrointestinal Therapeutics Market Segmentation And Category Overview

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    Gastrointestinal Therapeutics Market Transformation Trends: What Innovations Are Driving Change?

    Leading companies within the gastrointestinal therapeutics market are prioritizing the development of innovative treatments, such as sustained-release (SR) fixed-dose combination capsules, to boost patient adherence and enhance the efficacy of therapy. These sustained-release (SR) fixed-dose combination capsules are oral medications engineered to gradually release multiple active ingredients over time, thus maintaining consistent drug levels and reducing the frequency of dosing. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, unveiled rabeprazole + levosulpiride SR capsules for the treatment of gastrointestinal disorders across India. This particular formulation integrates rabeprazole, a proton pump inhibitor that reduces stomach acid, with levosulpiride, a prokinetic agent that improves gut motility. Together, these components deliver effective relief from symptoms like heartburn, acid reflux, bloating, and indigestion. This specific combination is extensively prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other associated gastrointestinal (GI) conditions.

    Gastrointestinal Therapeutics Market Competitive Analysis Of Leading Industry Participants

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    View The Full Gastrointestinal Therapeutics Market Report:

    https://thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Gastrointestinal Therapeutics Market Geographic Analysis: Where Is Demand Rising Fastest?

    North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gastrointestinal Therapeutics Market Trends Are Creating New Opportunities For Industry Leaders

    Gastrointestinal Therapeutics Market Trends Are Creating New Opportunities For Industry Leaders

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    Gastrointestinal Therapeutics Market Revenue Growth Supported By A CAGR Of 55.21% Through 2030

    The gastrointestinal therapeutics market has experienced robust expansion in recent years, with its value projected to increase from $42.3 billion in 2025 to $44.72 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This historic period’s growth has been driven by factors such as the constrained availability of biologics and advanced gastrointestinal treatments, a rising occurrence of acid reflux and ulcers, a dependency on hospital and clinic-based care, heightened awareness of digestive health, and the prevailing influence of conventional over-the-counter antacids and laxatives.

    The gastrointestinal therapeutics market is projected to experience robust expansion over the coming years, with an anticipated value of $55.21 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.4%. This forecasted rise is driven by advancements in targeted biologics and immunotherapies, the growing presence of ambulatory surgical centers and diagnostic labs, increased use of oral and intravenous delivery methods, greater penetration of online pharmacies, and new developments in probiotics and digestive enzyme products. Key trends shaping this period include the growing frequency of gastrointestinal conditions, a higher adoption rate of biologics and novel therapies, a broader availability of over-the-counter treatments, a stronger emphasis on personalized care for gastrointestinal issues, and the expanding role of online and retail pharmacy channels.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Gastrointestinal Therapeutics Market Growth Drivers And Industry Catalysts

    A surge in inflammatory bowel diseases is anticipated to accelerate the expansion of the gastrointestinal therapeutics market in the coming period. These conditions, such as Crohn’s disease and ulcerative colitis, are chronic disorders that lead to inflammation within the digestive tract. Their growing prevalence is linked to genetic factors that trigger an abnormal immune reaction against gut microbes. Treatment options in gastrointestinal therapeutics aim to manage these diseases by addressing the root inflammation, supporting digestive processes, and lessening symptoms to enhance patient well-being. Data from December 2023, released by the UK-based non-profit IBD Registry, showed that more than 5,300 people with these conditions were added to their registry, reflecting a rise of over 3,000 individuals compared to the previous year. Consequently, this uptick in inflammatory bowel disease cases is fueling market growth for gastrointestinal therapeutics.

    Gastrointestinal Therapeutics Market Segment Analysis And Revenue Opportunities

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    Gastrointestinal Therapeutics Market Trends Influencing Long-Term Demand

    Major players in the gastrointestinal therapeutics market are prioritizing the development of advanced treatment options, including sustained-release (SR) fixed-dose combination capsules, which are designed to boost patient adherence and optimize therapeutic outcomes. These capsules are oral medications that steadily deliver multiple active ingredients over a prolonged period, ensuring stable drug levels in the body and minimizing the need for frequent dosing. A notable example occurred in June 2024 when Akums Drugs and Pharmaceuticals Limited, a pharmaceutical manufacturing company based in India, introduced rabeprazole + levosulpiride SR capsules for managing gastrointestinal disorders within the country. This innovative formulation pairs rabeprazole, a proton pump inhibitor that reduces stomach acid production, with levosulpiride, a prokinetic agent that enhances gut motility. By working together, these components provide significant relief from symptoms like heartburn, acid reflux, bloating, and indigestion. This combination is frequently prescribed to address conditions such as gastroesophageal reflux disease, peptic ulcers, and various other gastrointestinal (GI) issues.

    Gastrointestinal Therapeutics Market Leading Players Shaping Industry Direction

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Access The Complete Gastrointestinal Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

    Gastrointestinal Therapeutics Market Leading Geography: Which Region Generates The Most Revenue?

    North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • The Rise In Inflammatory Bowel Diseases Drives The Growth Of The Market Due To Increasing Demand For Targeted Therapeutics Is Supporting Development Across The Gastrointestinal Therapeutics Market

    The Rise In Inflammatory Bowel Diseases Drives The Growth Of The Market Due To Increasing Demand For Targeted Therapeutics Is Supporting Development Across The Gastrointestinal Therapeutics Market

    The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

    How Will The Market Value Of The Gastrointestinal Therapeutics Market Change Between 2026 And 2030?

    The gastrointestinal therapeutics market has experienced significant growth in recent years. This market is set to expand from $42.3 billion in 2025 to $44.72 billion in 2026, progressing at a compound annual growth rate (CAGR) of 5.7%. The historical expansion can be attributed to several factors including the restricted availability of biologics and advanced gastrointestinal therapies, a rising incidence of acid reflux and ulcers, a reliance on hospital and clinic-based treatment, increasing awareness concerning digestive health, and the widespread use of traditional over-the-counter antacids and laxatives.

    The gastrointestinal therapeutics market is set for considerable expansion in the coming years. It is projected to reach $55.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This anticipated growth is driven by several factors, including the development of targeted biologics and immunotherapies, the increasing number of ambulatory surgical centers and diagnostic laboratories, the growing adoption of oral and intravenous delivery systems, expanding online pharmacy presence, and innovations in probiotic and digestive enzyme formulations. Key trends for the forecast period include a rising incidence of gastrointestinal disorders, increased utilization of biologics and advanced therapies, the expansion of over-the-counter therapeutic options, a heightened focus on personalized gastrointestinal treatments, and the growth of online and retail pharmacy distribution channels.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    What Market Drivers Are Helping Shape The Gastrointestinal Therapeutics Market Expansion?

    The increasing incidence of inflammatory bowel conditions is anticipated to fuel the expansion of the gastrointestinal therapeutics market moving forward. Inflammatory bowel disease (IBD) is a persistent ailment that causes inflammation in the digestive tract, primarily encompassing Crohn’s disease and ulcerative colitis. The surge in inflammatory bowel diseases is attributed to genetic susceptibility, resulting in an abnormal immune response to gut microbes. Gastrointestinal therapeutics assist in managing and treating bowel conditions by targeting underlying inflammation, regulating digestive functions, and easing associated symptoms to enhance patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Therefore, the rise in inflammatory bowel diseases is propelling the growth of the gastrointestinal therapeutics market.

    How Is The Gastrointestinal Therapeutics Market Distributed Across Key Segments?

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    Which Trends Are Supporting The Evolution Of The Gastrointestinal Therapeutics Market?

    Major companies operating within the gastrointestinal therapeutics market are prioritizing the development of innovative therapies, such as sustained-release (SR) fixed-dose combination capsules, with the goal of improving patient adherence and increasing treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications designed to gradually release multiple active ingredients over time, thereby maintaining consistent drug levels and reducing the frequency of dosing. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based company specializing in pharmaceutical preparation manufacturing, launched rabeprazole + levosulpiride SR capsules for the treatment of gastrointestinal disorders in India. This specific formulation combines rabeprazole, which acts as a proton pump inhibitor to decrease stomach acid, with levosulpiride, a prokinetic agent that enhances gut motility. Together, these components deliver effective relief from symptoms including heartburn, acid reflux, bloating, and indigestion. This combination therapy is widely prescribed for the management of gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.

    Which Companies Form The Competitive Landscape Of The Gastrointestinal Therapeutics Market?

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Access The Complete Gastrointestinal Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Which Region Stands As The Largest Contributor To The Gastrointestinal Therapeutics Market?

    North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Gastrointestinal Therapeutics Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

    Gastrointestinal Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

    Gastroparesis Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

    Digestive And Intestinal Remedies Market Report 2026

    https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gastrointestinal Therapeutics Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

    Gastrointestinal Therapeutics Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    By 2030, What Market Size Is The Gastrointestinal Therapeutics Market Expected To Reach Based On Its 2026 Value?

    The gastrointestinal therapeutics market has shown substantial expansion in recent times. Its value is anticipated to rise from $42.3 billion in 2025 to $44.72 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. Historically, this growth has been driven by several factors: the restricted availability of biologics and sophisticated gastrointestinal treatments, an uptick in the prevalence of acid reflux and ulcers, a dependency on hospital and clinic-based care, increasing public awareness of digestive health, and the prevailing use of traditional over-the-counter antacids and laxatives.

    The gastrointestinal therapeutics market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $55.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast timeframe is attributable to several factors, including the emergence of targeted biologics and immunotherapies, the proliferation of ambulatory surgical centers and diagnostic laboratories, the increasing uptake of oral and intravenous drug delivery systems, greater penetration by online pharmacies, and advancements in probiotics and digestive enzyme formulations. Key trends characterizing this period encompass the growing occurrence of gastrointestinal ailments, heightened utilization of biologics and advanced therapeutic options, the broadening availability of over-the-counter treatments, an escalating emphasis on individualized gastrointestinal care, and the expanding reach of online and retail pharmacy channels.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    What Factors Are Contributing To The Growth Of The Gastrointestinal Therapeutics Market?

    The increasing prevalence of inflammatory bowel diseases is anticipated to propel the expansion of the gastrointestinal therapeutics market going forward. Inflammatory bowel disease (IBD) is defined as a persistent condition that causes inflammation in the digestive tract, primarily encompassing Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases is attributed to genetic susceptibility, which triggers an abnormal immune response to gut microbes. Gastrointestinal therapeutics assist in managing and treating these bowel conditions by targeting the underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Therefore, the growing incidence of inflammatory bowel diseases is driving the growth of the gastrointestinal therapeutics market.

    What Are The Key Segment Divisions In The Gastrointestinal Therapeutics Market Segment Structure?

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    What Trends Are Affecting The Direction Of The Gastrointestinal Therapeutics Market?

    Major companies in the gastrointestinal therapeutics market are directing their efforts toward creating advanced therapies, such as sustained-release (SR) fixed-dose combination capsules, aiming to enhance patient compliance and boost treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications designed to gradually release multiple active ingredients over time, thus maintaining consistent drug levels and reducing dosing frequency. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole + levosulpiride SR capsules specifically for treating gastrointestinal disorders in India. This particular formulation brings together rabeprazole, a proton pump inhibitor that works by decreasing stomach acid, and levosulpiride, a prokinetic agent known for improving gut motility. Collaboratively, they provide effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination is extensively prescribed for the management of gastroesophageal reflux disease, peptic ulcers, and other associated gastrointestinal (GI) conditions.

    Which Organizations Are Engaged In The Gastrointestinal Therapeutics Market?

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Get The Full Gastrointestinal Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Where Is The Gastrointestinal Therapeutics Market Primarily Concentrated By Region?

    North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Gastrointestinal Therapeutics Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

    Gastrointestinal Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

    Gastroparesis Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

    Digestive And Intestinal Remedies Market Report 2026

    https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gastrointestinal Therapeutics Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

    Gastrointestinal Therapeutics Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    By 2030, What Market Size Is The Gastrointestinal Therapeutics Market Expected To Reach Based On Its 2026 Value?

    The gastrointestinal therapeutics market has shown substantial expansion in recent times. Its value is anticipated to rise from $42.3 billion in 2025 to $44.72 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. Historically, this growth has been driven by several factors: the restricted availability of biologics and sophisticated gastrointestinal treatments, an uptick in the prevalence of acid reflux and ulcers, a dependency on hospital and clinic-based care, increasing public awareness of digestive health, and the prevailing use of traditional over-the-counter antacids and laxatives.

    The gastrointestinal therapeutics market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $55.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast timeframe is attributable to several factors, including the emergence of targeted biologics and immunotherapies, the proliferation of ambulatory surgical centers and diagnostic laboratories, the increasing uptake of oral and intravenous drug delivery systems, greater penetration by online pharmacies, and advancements in probiotics and digestive enzyme formulations. Key trends characterizing this period encompass the growing occurrence of gastrointestinal ailments, heightened utilization of biologics and advanced therapeutic options, the broadening availability of over-the-counter treatments, an escalating emphasis on individualized gastrointestinal care, and the expanding reach of online and retail pharmacy channels.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    What Factors Are Contributing To The Growth Of The Gastrointestinal Therapeutics Market?

    The increasing prevalence of inflammatory bowel diseases is anticipated to propel the expansion of the gastrointestinal therapeutics market going forward. Inflammatory bowel disease (IBD) is defined as a persistent condition that causes inflammation in the digestive tract, primarily encompassing Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases is attributed to genetic susceptibility, which triggers an abnormal immune response to gut microbes. Gastrointestinal therapeutics assist in managing and treating these bowel conditions by targeting the underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Therefore, the growing incidence of inflammatory bowel diseases is driving the growth of the gastrointestinal therapeutics market.

    What Are The Key Segment Divisions In The Gastrointestinal Therapeutics Market Segment Structure?

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    What Trends Are Affecting The Direction Of The Gastrointestinal Therapeutics Market?

    Major companies in the gastrointestinal therapeutics market are directing their efforts toward creating advanced therapies, such as sustained-release (SR) fixed-dose combination capsules, aiming to enhance patient compliance and boost treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications designed to gradually release multiple active ingredients over time, thus maintaining consistent drug levels and reducing dosing frequency. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole + levosulpiride SR capsules specifically for treating gastrointestinal disorders in India. This particular formulation brings together rabeprazole, a proton pump inhibitor that works by decreasing stomach acid, and levosulpiride, a prokinetic agent known for improving gut motility. Collaboratively, they provide effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination is extensively prescribed for the management of gastroesophageal reflux disease, peptic ulcers, and other associated gastrointestinal (GI) conditions.

    Which Organizations Are Engaged In The Gastrointestinal Therapeutics Market?

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Get The Full Gastrointestinal Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Where Is The Gastrointestinal Therapeutics Market Primarily Concentrated By Region?

    North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Gastrointestinal Therapeutics Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

    Gastrointestinal Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

    Gastroparesis Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

    Digestive And Intestinal Remedies Market Report 2026

    https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gastrointestinal Therapeutics Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

    Gastrointestinal Therapeutics Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    By 2030, What Market Size Is The Gastrointestinal Therapeutics Market Expected To Reach Based On Its 2026 Value?

    The gastrointestinal therapeutics market has shown substantial expansion in recent times. Its value is anticipated to rise from $42.3 billion in 2025 to $44.72 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. Historically, this growth has been driven by several factors: the restricted availability of biologics and sophisticated gastrointestinal treatments, an uptick in the prevalence of acid reflux and ulcers, a dependency on hospital and clinic-based care, increasing public awareness of digestive health, and the prevailing use of traditional over-the-counter antacids and laxatives.

    The gastrointestinal therapeutics market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $55.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast timeframe is attributable to several factors, including the emergence of targeted biologics and immunotherapies, the proliferation of ambulatory surgical centers and diagnostic laboratories, the increasing uptake of oral and intravenous drug delivery systems, greater penetration by online pharmacies, and advancements in probiotics and digestive enzyme formulations. Key trends characterizing this period encompass the growing occurrence of gastrointestinal ailments, heightened utilization of biologics and advanced therapeutic options, the broadening availability of over-the-counter treatments, an escalating emphasis on individualized gastrointestinal care, and the expanding reach of online and retail pharmacy channels.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    What Factors Are Contributing To The Growth Of The Gastrointestinal Therapeutics Market?

    The increasing prevalence of inflammatory bowel diseases is anticipated to propel the expansion of the gastrointestinal therapeutics market going forward. Inflammatory bowel disease (IBD) is defined as a persistent condition that causes inflammation in the digestive tract, primarily encompassing Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases is attributed to genetic susceptibility, which triggers an abnormal immune response to gut microbes. Gastrointestinal therapeutics assist in managing and treating these bowel conditions by targeting the underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Therefore, the growing incidence of inflammatory bowel diseases is driving the growth of the gastrointestinal therapeutics market.

    What Are The Key Segment Divisions In The Gastrointestinal Therapeutics Market Segment Structure?

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    What Trends Are Affecting The Direction Of The Gastrointestinal Therapeutics Market?

    Major companies in the gastrointestinal therapeutics market are directing their efforts toward creating advanced therapies, such as sustained-release (SR) fixed-dose combination capsules, aiming to enhance patient compliance and boost treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications designed to gradually release multiple active ingredients over time, thus maintaining consistent drug levels and reducing dosing frequency. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole + levosulpiride SR capsules specifically for treating gastrointestinal disorders in India. This particular formulation brings together rabeprazole, a proton pump inhibitor that works by decreasing stomach acid, and levosulpiride, a prokinetic agent known for improving gut motility. Collaboratively, they provide effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination is extensively prescribed for the management of gastroesophageal reflux disease, peptic ulcers, and other associated gastrointestinal (GI) conditions.

    Which Organizations Are Engaged In The Gastrointestinal Therapeutics Market?

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Get The Full Gastrointestinal Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Where Is The Gastrointestinal Therapeutics Market Primarily Concentrated By Region?

    North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Gastrointestinal Therapeutics Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

    Gastrointestinal Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

    Gastroparesis Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

    Digestive And Intestinal Remedies Market Report 2026

    https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gastrointestinal Therapeutics Market 2026 evolving with innovation

    Gastrointestinal Therapeutics Market 2026 evolving with innovation

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Value Is Expected For The Gastrointestinal Therapeutics Market At The End Of The 2026–2030 Forecast Period?

    The gastrointestinal therapeutics market has experienced robust growth in recent years. It is projected to increase from $42.3 billion in 2025 to $44.72 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. The expansion observed in the historic period can be ascribed to factors such as the restricted availability of biologics and advanced gastrointestinal therapies, a rising incidence of acid reflux and ulcers, a dependency on hospital and clinic-based treatment, an increasing awareness concerning digestive health, and the prevailing use of traditional over-the-counter antacids and laxatives.

    The gastrointestinal therapeutics market size is anticipated to undergo significant expansion in the coming years, with projections indicating it will reach $55.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This growth throughout the forecast period is propelled by factors such as the creation of targeted biologics and immunotherapies, the increased availability of ambulatory surgical centers and diagnostic laboratories, a surge in the adoption of oral and intravenous delivery systems, the growing reach of online pharmacies, and innovations in probiotics and digestive enzyme formulations. Prominent trends for this period involve the rising occurrence of gastrointestinal disorders, a greater uptake of biologics and advanced therapies, the proliferation of over-the-counter therapeutics, an increasing focus on personalized gastrointestinal treatments, and the expanding distribution networks of online and retail pharmacies.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    What Drivers Are Shaping The Future Growth Of The Gastrointestinal Therapeutics Market?

    The increasing prevalence of inflammatory bowel diseases is anticipated to drive the expansion of the gastrointestinal therapeutics market going forward. Inflammatory bowel disease (IBD) describes a persistent ailment characterized by inflammation of the digestive system, encompassing conditions such as Crohn’s disease and ulcerative colitis. This rise in inflammatory bowel diseases stems from genetic predispositions, leading to an irregular immune reaction against gut microbes. Gastrointestinal therapeutics assist in the management and treatment of bowel conditions through addressing underlying inflammation, harmonizing digestive processes, and relieving accompanying symptoms, thereby enhancing patient well-being. As an illustration, in December 2023, data from the IBD Registry, a UK-based non-profit organization, indicated that more than 5,300 individuals with inflammatory bowel diseases (IBD) had registered in 2023, signifying an increase of over 3,000 members compared to 2022. Consequently, the growing occurrence of inflammatory bowel diseases is a key factor propelling the expansion of the gastrointestinal therapeutics market.

    What Segment Types Make Up The Gastrointestinal Therapeutics Market?

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    Which Market Trends Are Creating New Opportunities In The Gastrointestinal Therapeutics Market?

    Major companies in the gastrointestinal therapeutics market are concentrating on developing innovative treatments, such as sustained-release (SR) fixed-dose combination capsules, to enhance patient adherence and improve treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications engineered to gradually release multiple active ingredients over time, thereby maintaining consistent drug levels and reducing the frequency of dosing. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole + levosulpiride SR capsules for addressing gastrointestinal disorders in India. This formulation integrates rabeprazole, a proton pump inhibitor that reduces stomach acid, with levosulpiride, a prokinetic agent that improves gut motility. Together, they provide effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This specific combination is broadly prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.

    Who Are The Key Players Driving Competition In The Gastrointestinal Therapeutics Market?

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Read the full gastrointestinal therapeutics market report here:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Which Geographic Regions Are Influencing Demand In The Gastrointestinal Therapeutics Market?

    North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Gastrointestinal Therapeutics Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp

    Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

    Gastrointestinal Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

    Gastroparesis Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

    Digestive And Intestinal Remedies Market Report 2026

    https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Gastrointestinal Therapeutics Sector Forecast Shows Robust Momentum, Climbing to $55.21 Billion With 5.4% CAGR

    Gastrointestinal Therapeutics Sector Forecast Shows Robust Momentum, Climbing to $55.21 Billion With 5.4% CAGR

    Uncover key drivers, emerging technologies, and competitive movements shaping the gastrointestinal therapeutics market from 2026–2035 with trusted insights from The Business Research Company

    What size range is anticipated for the Gastrointestinal Therapeutics Market from 2026 to 2030?

    The gastrointestinal therapeutics market size has experienced robust growth in recent years. It is anticipated to increase from $42.3 billion in 2025 to $44.72 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. The expansion witnessed in the past can be attributed to several factors, including the constrained availability of biologics and sophisticated gastrointestinal treatments, a rising prevalence of acid reflux and ulcers, a reliance on hospital and clinic-based treatment modalities, increasing public awareness of digestive health, and the significant role of traditional over-the-counter antacids and laxatives.

    The gastrointestinal therapeutics market size is anticipated to experience substantial growth in the coming years, expanding to $55.21 billion by 2030 with a compound annual growth rate (CAGR) of 5.4%. This projected growth can be attributed to factors such as the development of targeted biologics and immunotherapies, the expansion of ambulatory surgical centers and diagnostic laboratories, the increasing adoption of oral and intravenous delivery systems, a rising penetration of online pharmacies, and innovations in probiotic and digestive enzyme formulations. Major trends for this period include the escalating prevalence of gastrointestinal disorders, a greater uptake of biologics and advanced therapies, the widening availability of over-the-counter therapeutics, a growing emphasis on personalized gastrointestinal treatments, and the increasing distribution through online and retail pharmacies.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    What Drivers Are Affecting Demand In The Gastrointestinal Therapeutics Market?

    The increasing prevalence of inflammatory bowel diseases is projected to fuel the expansion of the gastrointestinal therapeutics market moving forward. Inflammatory bowel disease (IBD) is a chronic disorder that causes inflammation of the digestive tract, primarily encompassing Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases stems from genetic susceptibility, which triggers an abnormal immune response to gut microbes. Gastrointestinal therapeutics assist in managing and treating these bowel conditions by targeting underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, the IBD Registry, a UK-based non-profit organization, reported that over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, indicating an increase of more than 3,000 members from 2022. Consequently, the rising inflammatory bowel diseases are driving the growth of the gastrointestinal therapeutics market.

    Which Segment Groups Are Influencing The Gastrointestinal Therapeutics Market?

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    Which Trends Are Influencing The Performance And Direction Of The Gastrointestinal Therapeutics Market?

    Companies operating in the gastrointestinal therapeutics market are concentrating on developing innovative treatments, such as sustained-release (SR) fixed-dose combination capsules, to improve patient compliance and enhance treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications designed to gradually release multiple active ingredients over time, maintaining consistent drug levels and reducing dosing frequency. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, launched rabeprazole + levosulpiride SR capsules for treating gastrointestinal disorders in India. This formulation combines rabeprazole, a proton pump inhibitor that decreases stomach acid, with levosulpiride, a prokinetic agent that improves gut motility. Together, they offer effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination is widely prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.

    Who Are The Major Companies Operating In The Gastrointestinal Therapeutics Market?

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Which Region Is Anticipated To See The Fastest Growth In The Gastrointestinal Therapeutics Market?

    North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Gastrointestinal Therapeutics Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp

    Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

    Gastrointestinal Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

    Gastroparesis Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

    Digestive And Intestinal Remedies Market Report 2026

    https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Gastrointestinal Therapeutics Industry Trends: Where the Market Is Headed by 2029

    Global Gastrointestinal Therapeutics Industry Trends: Where the Market Is Headed by 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Is The Gastrointestinal Therapeutics Market Size Likely To Evolve From 2025 Through 2034?

    The gastrointestinal therapeutics market has demonstrated substantial growth in recent times. This market is projected to expand from $39.99 billion in 2024 to reach $42.30 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 5.8%. Historically, this expansion has been driven by factors such as increased government spending on healthcare, improved rates of early diagnosis, a surge in gut health awareness initiatives, a rise in digestive disorders linked to lifestyle, and the adoption of more multidisciplinary treatment methods.

    The gastrointestinal therapeutics market size is anticipated to experience substantial expansion in the coming years, with projections indicating it will reach $52.41 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.5%. This growth throughout the forecast period is primarily driven by factors such as an escalating demand for biologics and targeted therapies, the increasing adoption of personalized medicine, a rising patient preference for combination therapies, an intensified focus on microbiome-targeted therapeutics, and the growing incidence of antibiotic-associated gastrointestinal complications. Significant trends expected during this period include the integration of advanced technology into endoscopic devices, the development of microbiome-based therapies, the incorporation of digital health and remote monitoring solutions, the utilization of multi-omics data in therapy development, and ongoing innovations in acid suppression treatments.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    Which Major Market Drivers Are Shaping The Future Of The Gastrointestinal Therapeutics Market?

    The increasing incidence of inflammatory bowel diseases is projected to stimulate the growth of the gastrointestinal therapeutics market moving forward. Inflammatory bowel disease (IBD) is a long-term condition characterized by inflammation of the digestive tract, primarily involving Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases is attributed to genetic susceptibility, which causes an abnormal immune response to gut microbes. Gastrointestinal therapeutics aid in the management and treatment of bowel diseases by targeting underlying inflammation, regulating digestive functions, and alleviating associated symptoms to enhance patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, more than 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, indicating an increase of over 3,000 members from 2022. Consequently, the escalating occurrence of inflammatory bowel diseases is propelling the expansion of the gastrointestinal therapeutics market.

    What Are The Primary Types Of Segments Analyzed In The Gastrointestinal Therapeutics Market?

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    How Are Emerging Market Trends Shaping The Gastrointestinal Therapeutics Industry Landscape?

    Leading companies in the gastrointestinal therapeutics market are prioritizing the creation of innovative therapies, such as sustained-release (SR) fixed-dose combination capsules, to enhance patient adherence and improve treatment efficacy. These sustained-release (SR) fixed-dose combination capsules are oral medications engineered to progressively release multiple active ingredients over time, thus maintaining consistent drug levels and minimizing dosing frequency. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole + levosulpiride SR capsules for managing gastrointestinal disorders in India. This formulation unites rabeprazole, a proton pump inhibitor that reduces stomach acid, with levosulpiride, a prokinetic agent that boosts gut motility. Together, they provide effective relief from symptoms including heartburn, acid reflux, bloating, and indigestion. This combination is broadly prescribed for the treatment of gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.

    Which Leading Players Are Enhancing Their Gastrointestinal Therapeutics Market Presence Worldwide?

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, Olympus Corporation, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    Which Regional Markets Are Contributing Most To The Gastrointestinal Therapeutics Industry Expansion?

    North America was the largest region in the gastrointestinal therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Gastrointestinal Therapeutics Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp

    Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2025, By The Business Research Company

    Gastrointestinal Drugs Global Market 2025

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

    Gastroparesis Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

    Digestive And Intestinal Remedies Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • What Is The Predicted Revenue Outlook For The Global Gastrointestinal Therapeutics Market To Surpass $52.41 Billion?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Are The Market Size Estimates For The Gastrointestinal Therapeutics Market?

    There has been robust growth in the size of the gastrointestinal therapeutics market in the last few years. The market is projected to swell from $39.99 billion in 2024 to $42.30 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this growth during the historical period include a spike in government spending on healthcare, improved rates of early diagnosis, enhanced gut health awareness programs, a surge in digestive disorders tied to lifestyle, and the rise of multidisciplinary treatment strategies.

    Strong growth is anticipated in the gastrointestinal therapeutics market size over the coming years, with its value predicted to reach $52.41 billion in 2029, achieving a compound annual growth rate (CAGR) of 5.5%. The expansion during the forecast period can be ascribed to heightened demand for biologics and targeted therapies, a rising inclination towards personalised medicine, increased patient interest in combination therapies, a growing focus on therapeutics targeting the microbiome, and an increase in gastrointestinal complications associated with antibiotics. Major trends to watch during the forecast period include the integration of technology in endoscopic devices, the development of therapies based on the microbiome, the integration of digital health and remote monitoring, the utilization of multi-omics data in therapy development, and innovations in acid suppression therapies.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

    Which Industry Forces Are Driving The Gastrointestinal Therapeutics Market Forward?

    The escalation in inflammatory bowel diseases is predicted to boost the expansion of the gastrointestinal therapeutics market in the future. Inflammatory bowel disease (IBD) is a long-lasting disease causing inflammation in the digestive tract, predominantly including Crohn’s disease and ulcerative colitis. The escalation in inflammatory bowel diseases can be attributed to genetic susceptibility leading to an irregular immune response to gut microbes. Gastrointestinal therapeutics facilitates the management and treatment of bowel diseases by focusing on the underlying inflammation, adjusting digestive functions and easing related symptoms to enhance patient outcomes. For example, in December 2023, the UK-based IBD Registry, a non-profit organization, registered over 5,300 individuals with inflammatory bowel diseases (IBD), indicating an increase of over 3,000 members from 2022. Consequently, the escalation in inflammatory bowel diseases is propelling the expansion of the gastrointestinal therapeutics market.

    How Is The Gastrointestinal Therapeutics Market Organized By Different Segments?

    The gastrointestinal therapeutics market covered in this report is segmented –

    1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

    2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

    3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

    Subsegments:

    1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

    2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

    What Current And Upcoming Trends Are Shaping The Gastrointestinal Therapeutics Market?

    Focused on innovation, key players in the gastrointestinal therapeutics market are working towards improved patient adherence and overall efficiency of treatments by developing advanced therapies. This includes the use of sustained-release (SR) fixed-dose combination capsules. These oral medications slowly release a set of active ingredients over a period of time to establish consistent drug levels and help decrease the frequency of dosages. For example, Akums Drugs and Pharmaceuticals Limited, a pharmaceutical preparation manufacturing company based in India, unveiled their launch of rabeprazole + levosulpiride SR capsules for the treatment of gastrointestinal illnesses in June 2024. Rabeprazole, a proton pump inhibitor that minimizes stomach acid, is combined with levosulpiride, a prokinetic agent that boosts gut motility. The combination assists in alleviating symptoms including heartburn, acid reflux, bloating, and indigesticonsistently. It’s frequently recommended for managing diseases like gastroesophageal reflux, peptic ulcers, and other gastrointestinal (GI) conditions.

    Who Are The Primary Market Leaders In The Gastrointestinal Therapeutics Market?

    Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, Olympus Corporation, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

    How Do Regional Dynamics Influence The Gastrointestinal Therapeutics Market Performance?

    North America was the largest region in the gastrointestinal therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp

    Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2025, By The Business Research Company

    Gastric Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

    Gastroesophageal Reflux Disease Therapeutics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

    Intestine Cancer Therapeutics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

    About The Business Research Company:

    With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model